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Background: The insulin-like growth factor-1 (IGF-1) plays an important role in growth of prostate cancer (PCa)
cells and facilitating the development and progression of PCa. This study aimed to evaluate the association of
polymorphisms in three linkage disequilibrium (LD) blocks of the IGF-1 on the survival of metastatic PCa patients.
Methods: A total of 215 patients with bone metastases at initial presentation were included in this study. The
cytosine-adenine (CA) repeat polymorphism and rs12423791 were selected as representative polymorphisms in the
LD blocks 1 and 2, respectively. Haplotype in the LD block 3 was analyzed using two tag single nucleotide
polymorphisms (SNPs), rs6220 and rs7136446. Cancer-specific survival rate was estimated from the Kaplan-Meier
curve, and the survival data were compared using the log-rank test.
Results: Cancer-specific survival was significantly associated with the CA repeat polymorphism, rs12423791, and
rs6220 (P = 0.013, 0.014, and 0.014, respectively). Although rs7136446 had no significant association with survival, the
haplotype in the LD block 3 was significantly associated with cancer-specific survival (P = 0.0003). When the sum of
the risk genetic factors in each LD block (19-repeat allele, C allele of rs12423791, or C-T haplotype) was considered,
patients with all the risk factors had significantly shorter cancer specific-survival than those with 0–2 risk factors
(P = 0.0003).
Conclusions: Polymorphisms in the IGF-1, especially a haplotype in the LD block 3, are assumed to be genetic
markers predicting the outcome of metastatic PCa.
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Prostate cancer is typically a type of slow-growing can-
cer and generally well controlled by endocrine therapies
even if distant metastases are present. However, those
patients with distant metastases exhibit disease progres-
sion within 12 to 18 months on average and gradually
manifest resistant to endocrine therapies thereafter [1].
Because several new promising agents are available or* Correspondence: thabuchi@doc.med.akita-u.ac.jp
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reproduction in any medium, provided the orbeing tested for treatment of castration-resistant pros-
tate cancer [2-4], it has been of importance to identify
pretreatment prognostic factors in metastatic prostate
cancer for adjusting treatment intensity in each patient.
Clinical and laboratory factors such as extent of disease
(EOD) score [5], serum alkaline phosphate (ALP) [6],
hemoglobin (HGB) [7], and prostate specific antigen
(PSA) [8] have been used as prognostic markers for
those patients since 20 years ago. Recent studies suggest
that patients’ intrinsic genetic factors or an interaction
with environmental factors may have an impact on pro-
gression or survival in advanced prostate cancer patientsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Genomic structure of the IGF1 gene. The map shows
the structure of the IGF-1 gene and its linkage disequilibrium (LD)
blocks. The locations of four polymorphisms analyzed in this study
are indicated in the figure.
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lin-like growth factor-1 (IGF-1) and the cytochrome P450
aromatase (CYP19) polymorphisms were significantly
associated with the cancer -specific survival of metastatic
prostate cancer [10]. However, to date, investigations of
genetic polymorphisms associated with cancer progres-
sion or survival have just begun and only a few reports
are available in regard to a prostate cancer [11,12].
Evaluating outcomes using genetic makers combined
with conventional prognostic markers is expected to lead
to more accurate prediction of response to treatments or
survival.
IGF-1 is involved in embryonic growth, homeostasis,
and various diseases by regulating cell differentiation,
proliferation, migration, and apoptosis. In the prostate, it
plays an important role in the growth of both normal
and cancer cells and facilitates the development and pro-
gression of prostate cancer [13,14]. Recent meta-analysis
revealed that men with higher circulating IGF-1 levels
had an increased risk of prostate cancer compared with
men with lower IGF-1 levels [15] and the levels of circu-
lating IGF-1 had a heritable component [16]. The same
positive association was observed between circulating
IGF-1 level and a risk for breast and colorectal cancer
[17-21]. Meanwhile, a cytosine-adenine (CA) repeat
polymorphism has been known to be located in the pro-
moter region of the IGF-1 gene [22] and many studies
investigated the influence of the polymorphism on the
circulating IGF-1 level and risk for certain types of can-
cer [23]. Recent genome research revealed a number of
single nucleotide polymorphism (SNP) throughout the
IGF-1 region and haplotype analyses demonstrated that
those SNPs were divided into three to four blocks in
which SNPs for each block are in linkage disequilibrium
(LD) each other [24,25]. Especially a haplotype in the LD
block 3 located in a downstream of the CA repeat has
been suggested as a novel genetic variation associated
with circulating IGF-1 level or cancer risk [25,26].
In this retrospective study, we aimed to evaluate the
association of four polymorphisms in three LD blocks of
the IGF-1 on the survival of prostate cancer patients
with bone metastasis at initial diagnosis.
Methods
Patients
From July 1980 to September 2008, 215 native Japanese
patients of prostate cancer with bone metastasis at initial
presentation in Akita University Hospital and its related
community hospitals, Kyoto University and Tohoku
University Hospitals were enrolled in this study. Patho-
logical diagnosis was made by prostate needle biopsy
specimens and metastasis was identified by X-rays, CT
scans, or bone scintigraphy. All the patients had no pre-
vious treatments at presentation and underwent surgicalcastration or luteinizing hormone-releasing hormone (LH-
RH) analogues with or without antiandrogens as primary
endocrine therapy. When the treatment failure was ob-
served, optional therapies, including other antiandrogens,
estrogens, steroids, chemotherapeutic agents, palliative ra-
diation, or a combination of these was added or replaced.
Pathological grading of needle biopsy specimens was
performed according to Gleason grading system by local
pathologists with no designated primary pathologist. In 10
patients, the final pathological grade was not determined
because no grade information was described in the final
report or a different grading system was applied by the
local pathologists. Pretreatment HGB, ALP, lactate de-
hydrogenase (LDH), and PSA levels before the initial
treatment of prostate cancer were obtained from medical
charts. An independent end-point reviewer in each insti-
tution determined the cause of death on the basis of stan-
dardized extractions from the patients’ medical files
without providing genotype data of each patient.
Written informed consent was obtained from all the
patients enrolled in this study for the use of their DNA
and clinical information. This study was approved by the
Institutional Review Board (the Ethical Committee) in
each institution.
Genotyping analysis
DNA was extracted from a peripheral blood sample of
each patient using a QIAamp Blood Kit (QIAGEN,
Hilden, Germany) or standard phenol-chloroform. We di-
vided the IGF-1 gene into three LD blocks according to a
previous report by Johansson et al. (Figure 1) [25]. The
representative polymorphisms in each LD block were
chosen with reference to literatures as the genes previ-
ously described to be associated with the circulating IGF-
1 level or the increased risk of prostate cancer [27] and
SNP database of international HapMap project (http://
hapmap.ncbi.nlm.nih.gov/) [28]. The CA repeat poly-
morphism in the promoter region and rs12423791
[GenBank] were selected from representative polymor-
phisms in the LD block 1 and 2, respectively. rs6220
[GenBank] and rs7136446 [GenBank] were selected as tag
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of the CA repeat polymorphism were determined by an
automated sequencer (ABI PRISM 310 Genetic Analyzer)
with GENESCAN software (Applied Biosystems, Foster
City, CA) as described previously [17]. Other three SNPs
were genotyped using polymerase chain reaction (PCR)-
restriction fragment length polymorphism (RFLP) method.
The sequence of forward and reverse primers used
for genotyping of the SNPs were as follows; 50-GCTGC
TTCTTCCAATGAGAG-30 and 50-GAAAAGCATGTTGC
TGCCTC-30 for rs12423791 (123 bp), and TGCCTAG
AAAAGAAGGAATC-30 and 50-TGACTCTTCTATGCAG
TTAC-30 for rs6220 (105 bp), and 50-CTTCTTGCAGAAC
TAAGCTCAAGTC-30 and 50-GCCTATTCATTTTCA
CATACTACCC-30 for rs7136446 (126 bp). Each PCR prod-
uct was digested with DdeI, MspI, and MnlI, respectively,
overnight at 37°C, and electrophoresed on 3.0% agarose
gels to determine the genotype. Several samples were dir-
ectly sequenced using Dye Terminator Sequencing Kit ver-
sion 1.0 (PE Applied Biosystems) on an ABI prism 310
auto-sequencer to confirm the results of PCR-RFLP for
each polymorphism.Table 1 Patients’ clinical characteristics
Mean ± SD (median) Range
Age (years) 70.2 ± 8.4 (72) 45 – 89
PSA (ng/mL) 1,029 ± 1,896 (260) 2.4 – 12,490
HGB (g/dL) 13.1 ± 1.9 (13.3) 7.4 – 17.4
ALP (IU/L) 615 ± 908 (291) 50 – 5,870
LDH (IU/L) 295 ± 180 (222) 97 – 1,273
Follow-up (months) 46.4 ± 36.1 (37) 1 – 209
N (%)
Metastases
Bone only 106 (49.3)
Lymph nodes 98 (45.6)
Other organs 15 (7.0)
Gleason score
< 7 15 (7.0)
7 – 8 81 (37.7)
9 – 10 109 (50.7)
Unknown 10 (4.6)Statistical analysis
The endpoint of this study was prostate cancer-specific
survival. The survival time was calculated from the date
of prostate cancer diagnosis to the date of death or the
last contact with patients. To compare the survival, pa-
tients were dichotomized by the median value of age
and PSA, by normal limits in HGB, ALP, LDH, by the
tumor grade system (Gleason score). Haplotypes of the
LD block 3 defined two SNPs, rs6220 and rs7136446,
were inferred using expectation-maximization algorithm
in SNPAlyze software ver.7 (Dynacom Co. Ltd., Chiba,
Japan). Differences in survival between groups were ana-
lyzed using the logrank test. For the CA repeat poly-
morphism, the number of repeats was dichotomized as
having or not having the 19-repeat allele. Each SNP or
haplotype was evaluated using dominant, recessive, and
addictive model, and the most statistically significant
model was selected. The IGF-1 polymorphisms and
clinicopathological prognostic factors were assessed by
the Cox proportional hazard regression models. Age,
Gleason score, PSA, HGB, ALP, LDH, and the LD block
3 haplotype were employed as a variable set in a full-
variable model of multivariate analysis. Of the variables,
Gleason score, HGB, ALP, and the LD block 3 haplotype
were selected in a reduced variable model. Cancer-
specific survival was estimated using the Kaplan–Meier
method. All the statistical analyses were performed using
SPSS software version 19.0 (IBM Japan Ltd., Tokyo,
Japan) and two-sided P values of less than 0.05 were
considered to indicate statistical significance.Results
Clinicopathological background of patients
The mean age (± SD) of the 215 patients was 70.2 ± 8.4 -
years (range, 45–89; median, 72 years). The mean
follow-up period was 46.4 ± 36.1 months (range, 1–209;
median, 37 months). Of 215 patients, bone metastasis
alone, additional lymph nodes metastasis, and other vis-
ceral metastasis were seen at initial diagnosis in 106
(49.3%), 98 (45.6%), and 15 (7.0%), respectively. The dis-
tribution of Gleason score of biopsy specimen was < 7 in
15 patients (7.0%), 7–8 in 81 (37.7%), 9–10 in 109
(50.7%), and unknown in 10 (4.6%). Pretreatment PSA,
HGB, ALP, and LDH levels are shown in Table 1. All the
patients were received an endocrine therapy as an initial
treatment, surgical castration alone in 29 (13.5%), LH-
RH analogue alone in 53 (24.6%), combined androgen
blockade in 131 (60.9%). Among 188 patients with avail-
able data, 91patinets (48.4%) achieved a PSA nadir less
than 1 ng/ml, while 97 patients (51.6%) did not reach
the level after initial endocrine therapies.
Genotyping analysis
The repeat number of the CA repeat polymorphism
ranged from 13 to 20, and 20 genotypes were observed.
The distributions of the genotypes of the CA repeat poly-
morphisms, rs12423791, rs6220, and rs7136446 were
shown in Table 2. Estimated haplotype frequencies of the
LD block 3 (rs6220 - rs7136446) were 55.2% (T-T), 26.7%
(C-T), 16.8% (C-C), and 1.3% (T-C). Thirty-seven patients
with heterozygous genotype of both rs6220 and rs7136446
were estimated as having the T-T and C-C haplotypes be-
cause estimated haplotype frequency of the T-C haplotype
Table 2 Genotype distributions of four polymorphisms
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determined.
Survival analysis
Kaplan-Meier curves demonstrated that patients with 19-
repeat allele, C allele of rs12423791, or C allele of rs6220
had a significantly worse survival (P = 0.013, 0.014, or
0.014, respectively). Whereas, rs7136446 was not associ-
ated with patients’ survival (P = 0.371). Patients with at
least one C-T haplotype showed significantly worse sur-
vival compared with those who had no C-T haplotype
(P = 0.0003) (Figure 2). When the number of the geneticrisk factors (19-repeat allele, C allele of rs12423791, or C-T
haplotype) was considered, cancer-specific survival signifi-
cantly shortened with increased the number of genetic risk
factors (P = 0.002), and patients with all the genetic risk fac-
tors had significantly shorter survival than those with 0–2
risk factors (P = 0.0003) (Figure 3).
An univariate Cox proportional hazard regression ana-
lysis showed that cancer-specific survival was signifi-
cantly lower in patients with Gleason score of 9 or
higher (HR: 1.759, 95% CI: 1.151-2.687, P = 0.009), HGB
less than 11.5 g/dl (HR: 2.251, 95% CI: 1.261-4.019,
P = 0.006), ALP of 350 IU/ml or higher (HR: 2.836, 95%
CI: 1.756-4.578, P = 0.00002), or LDH of 500 IU/ml or
higher (HR: 2.638, 95% CI: 1.442-4.829, P = 0.002) (Table 3).
Meanwhile, neither dichotomized age nor PSA was
associated with cancer-specific survival. In a multi-
variate analysis including all the clinicopathological
variables and haplotype of the LD block 3 as a repre-
sentative genetic variable, higher Gleason score (HR:
1.766, 95% CI: 1.052-2.966, P = 0.031), higher ALP
(HR: 2.598, 95% CI: 1.483-4.551, P =0.0008), and
the C-T haplotype (HR: 2.619, 95% CI: 1.559-4.399,
P = 0.0003) were independent factors predicting
cancer-specific survival. HGB and LDH showed bor-
derline significance (P = 0.061 and 0.059, respectively).
In a reduced variable model, higher ALP (HR: 2.819, 95%
CI: 1.695-4.689, P = 0.00007) and C-T haplotype (HR:
2.626, 95% CI: 1.603-4.305, P = 0.0001) were stronger in-
dependent predictors for the survival, followed by HGB
(HR: 2.082, 95% CI 1.113-3.897, P = 0.022) and Gleason
score (HR: 1.709, 95% CI: 1.054-2.771, P = 0.030) (Table 3).
Because the Gleason score and the pretreatment ALP
level were shown to be significant prognostic factors
along with the LD Block 3 haplotype by multivariate
analysis (Table 3), we performed subgroup analyses
according to the dichotomized Gleason score or the di-
chotomized pretreatment ALP level to compare survivals
by presence or absence of C-T haplotype. Among pa-
tients with Gleason score of 9–10 (n = 108), those with
C-T haplotype showed significantly worse survival than
those having no C-T haplotype (P = 0.0002), while there
was no significant difference (P = 0.365) in patients with
Gleason score less than 9 (n = 96). Regarding ALP, pa-
tients with C-T haplotype showed significantly shorter
survival than those with no C-T haplotype in either sub-
group (ALP higher or lower than 350 IU/ml) (P = 0.010
or 0.009, respectively) (Figure 4).
Discussion
The association of the CA repeat polymorphism in the
promoter region of the IGF-1 with circulating IGF-1
levels and a risk of breast, prostate, and colorectal can-
cers have been extensively evaluated [23,29]. In those













































































0 5 10 15 20
Figure 2 Cancer-specific survival of patients classified based on the risk allele, genotype or haplotype. The survival was significantly
worse in patients with 19 CA repeat allele in the LD block1 than those without 19 CA repeat allele (P = 0.013) (A). Patients with GC or CC
genotype of the rs12423791 in the LD block 2 had significantly worse survival than those with GG genotype (P = 0.014) (B). As regards to the LD
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Figure 3 Cancer-specific survival of patients classified based on the sum of genetic risk factors. The genetic risk factors were defined as
presence of 19 repeat allele of the CA repeat polymorphism, C allele of the rs12423791, and C-T haplotype of the LD block 3. Each patient was
assigned to one of 3 groups (0, 1–2, or 3 risk factors) (A) or one of 2 groups (0–2 or 3 risk factors) (B). The cancer-specific survivals significantly
differed in both of the classification (P = 0.002 and 0.0003).
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Table 3 Univariate and multivariate analysis of clinicopathological and genetic factors predicting cancer-specific
survival
Univariate analysis
Category HR1 95% CI2 P
Clinical and pathological factors
Age (yrs) ≥ 72 vs. < 72 1.183 0.790 - 1.772 0.415
Gleason score ≥ 9 vs. < 9 1.759 1.151 – 2.687 0.009
PSA (ng/mL) ≥ 260 vs. < 260 1.510 0.992 – 2.299 0.054
HGB (g/dL) < 11.5 vs. ≥ 11.5 2.251 1.261 – 4.019 0.006
ALP (IU/L) ≥ 350 vs. < 350 2.836 1.756 – 4.578 0.00002
LDH (IU/L) ≥ 500 vs. < 500 2.638 1.442 – 4.829 0.002
Genetic factors
LD block 1 (CA repeat) 19 rpts (+) vs. (−) 1.671 1.109 – 2.518 0.014
LD block 2 (rs12423791) GC + CC vs. GG 1.658 1.102 – 2.495 0.015
LD block 3 (haplotype) C-T (+) vs. C-T (−) 2.054 1.373 – 3.075 0.0005
Number of risk factors 0 vs. 1–2 vs. 3 1.578 1.208 – 2.060 0.0008
0–2 vs. 3 2.202 1.414 – 3.430 0.0005
Multivariate analysis
Full model
Age (yrs) ≥ 72 vs. < 72 0.919 0.554 – 1.526 0.745
Gleason score ≥ 9 vs. < 9 1.766 1.052 – 2.966 0.031
PSA (ng/mL) ≥ 265 vs. < 265 0.932 0.496 – 1.749 0.826
HGB (g/dL) < 11.5 vs. ≥ 11.5 2.012 0.968 – 4.180 0.061
ALP (IU/L) ≥ 350 vs. < 350 2.598 1.483 – 4.551 0.0008
LDH (IU/L) ≥ 500 vs. < 500 1.836 0.977 – 3.448 0.059
LD Block 3 (haplotype) C-T (+) vs. C-T (−) 2.619 1.559 – 4.399 0.0003
Reduced model
Gleason score ≥ 9 vs. < 9 1.709 1.054 – 2.771 0.030
HGB (g/dL) < 11.5 vs. ≥ 11.5 2.082 1.113 – 3.897 0.022
ALP (IU/L) ≥ 350 vs. < 350 2.819 1.695 – 4.689 0.00007
LD Block 3 (haplotype) C-T (+) vs. C-T (−) 2.626 1.603 – 4.305 0.0001
1HR, hazard ratio; 295% CI, 95% confidence interval.
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having the allele. To date, however, the results were in-
consistent in terms of whether 19-repeat allele increases
IGF-1 levels or cancer risks. A recent large-scale study
of 6,400 healthy subjects indicated that other polymor-
phisms downstream of the CA repeat polymorphism
may affect IGF-1 circulation levels [30]. In prostate can-
cer patients, Johansson et al. demonstrated that hetero-
zygous haplotype of T-C-C (rs6220-rs7136446-rs2033178
[GenBank]) in the 30 region of the IGF-1, which was a
risk haplotype of prostate cancer risk in their previous
study, was significantly associated with higher circulating
levels of IGF-1 [27]. In the study, however, another co-
hort did not show the significant difference in circulat-
ing IGF-1 levels and rather patients with rs6220 CC
genotype showed significantly higher circulating IGF-1level in a separate SNP analysis of each SNP [27]. Other
study also showed significantly increased circulating
IGF-1 levels in females with rs6220 CC genotype [31].
Since all the patients in our series had the CC genotype
at rs2033178 (data not shown), the T-C-C haplotype is
referred to as the T-C haplotype in our study. Although
the T-C (T-C-C) haplotype was not separately analyzed
in a survival analysis due to the rare haplotype with only
1.3%, our result showed that patients with the C-T
haplotype had significantly worse survival and appeared
to be in line with previous studies investigating the asso-
ciation between circulating IGF-1 levels and the IGF-1
polymorphisms.
Multiple interpretations are possible regarding the role
of the polymorphisms in altering the circulating IGF-1
levels. A previous study demonstrated in other genes
n=64
n=32
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Figure 4 Cancer-specific survival of patients classified based on haplotype in the LD block 3 in subgroups dichotomized by Gleason
score or pretreatment ALP level. Patients with C-T haplotype showed significantly worse survival than those having no C-T haplotype
(P = 0.0002) in patients with Gleason score of 9–10 (A), while there was no significant difference (P = 0.365) in patients with Gleason score less
than 9 (B). In a subgroup analysis by pretreatment ALP level, patients with C-T haplotype showed significantly shorter survival than those with no
C-T haplotype in either subgroup of patients with lower (< 350 IU/L) or higher (≥ 350 IU/L) ALP (P = 0.010 or 0.009, respectively) (C and D).
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negative control element [32], suggesting a possibility
that a CA repeat length directly affects the transcrip-
tional activity of the IGF-1. This hypothesis is partially
supported by a study conducted by Missmer et al. [33].
They showed a trend of decreasing IGF-1 level with in-
creasing the CA repeat length genotype, although this
was not statistically significant [33]. Another explanation
is that CA repeats do not directly affect the transcrip-
tional activity but other SNPs being in linkage disequi-
librium exert functional effect on a transcriptional
activity. Recent studies demonstrated that SNPs or hap-
lotypes in other regions in the IGF-1, especially down-
stream of the CA repeats, were associated with
circulating IGF-1 levels or cancer susceptibility [24,30].
Chen et al. reported a possible association of a haplotype
combined of SNPs and the CA repeat length with circu-
lation IGF-1 levels. In the study, the combined haplotype
was correlated with circulating IGF-1 levels and neither
SNPs nor the CA repeat alone was associated with theIGF-1 levels [34]. Nevertheless, in vitro studies are needed
to determine the functional implication of those genetic
polymorphisms on the alteration of IGF-1 expression.
Several mechanisms of IGF-1 affecting the prognosis of
metastatic prostate cancer are envisioned. First, IGF-1 is
known to act as an important growth factor regulating pro-
liferation and apoptosis of cancer cells and has a role in an
acquisition of resistance to endocrine therapies [35-37].
Secondary, IGF-1, which is also produced by bone cells,
down-regulates osteoprotegerin (OPG) and up-regulated
receptor activator of NF-κB ligand (RANKL) [38]. Results
of the present study suggest that the polymorphisms are
associated with an aggressive phenotype and resistance to
endocrine therapy and facilitate the progression of prostate
cancer cells especially in bone metastasis.
The present study has several limitations. First, the
present study has a possible bias of patient selection,
which is a drawback of retrospective study design. Al-
though the majority of the patients are incident cases,
some patients who had rapid progression and very short-
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Second, treatment strategy was not regulated in this retro-
spective study. Because of the long recruiting period, vari-
ous treatments except for endocrine therapies including
docetaxel were administered only in recent cases. A pro-
spective study with a large cohort is mandatory to validate
the results. Thirdly, we examined only 4 polymorphism
loci and other SNPs may have a stronger association with
the survival than those evaluated in the present study. A
study using precise SNP panel may lead to identify SNPs
truly responsible for the survival and the function of the
SNPs should be supported by biological investigations.Conclusions
Polymorphisms of the IGF-1, especially C-T haplotype in
the LD block 3 were associated with worse survival of
prostate cancer patients with bone metastasis at initial
diagnosis. The genomic variations in the IGF-1 combined
with conventional clinicopathological prognostic markers,
along with conventional clinical markers, appeared to be
useful for predicting the outcome of metastatic prostate
cancer.
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